Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
Sponsor: Washington University School of Medicine
Terminated
Low accrual
Other terminated trials from Washington University School of Medicine
- Gynecologic Cancer · Phase NA · Oct 2025
- Extensive-stage Small Cell Lung Cancer · Phase PHASE2 · Aug 2025
- Schizophrenia · Phase PHASE1 · Jan 2025
- Systemic Lidocaine Improves Pain Control After Surgery by Attenuating the Systemic Inflammatory Response to Surgery · Phase PHASE4 · Dec 2024
- Recurrent Rectal Cancer · Phase NA · Nov 2024
See all terminations from Washington University School of Medicine
A PHASE1 clinical study on Astrocytoma, Grade IV and Glioblastoma Multiforme, this trial is terminated or withdrawn. The trial is conducted by Washington University School of Medicine and has accumulated 10 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
▶ Show 5 earlier versions
-
Dec 2017 — Jun 2018 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Aug 2017 — Dec 2017 [monthly]
Recruiting PHASE1
-
Mar 2017 — Aug 2017 [monthly]
Recruiting PHASE1
Phase: EARLY_PHASE1 → PHASE1
-
Feb 2017 — Mar 2017 [monthly]
Recruiting EARLY_PHASE1
Phase: Phase 0 → EARLY_PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting Phase 0
First recorded
Dec 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .